| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
J Clin Oncol
|
2008
|
4.82
|
|
2
|
Patient-derived tumour xenografts as models for oncology drug development.
|
Nat Rev Clin Oncol
|
2012
|
4.00
|
|
3
|
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
|
J Clin Oncol
|
2010
|
2.41
|
|
4
|
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.96
|
|
5
|
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
|
Clin Cancer Res
|
2010
|
1.96
|
|
6
|
Esophageal and esophagogastric junction cancers, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
1.52
|
|
7
|
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
|
Mol Cancer Ther
|
2010
|
1.19
|
|
8
|
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
|
Clin Cancer Res
|
2010
|
1.02
|
|
9
|
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
|
Clin Cancer Res
|
2013
|
1.01
|
|
10
|
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
0.99
|
|
11
|
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
|
Invest New Drugs
|
2010
|
0.91
|
|
12
|
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
|
Clin Cancer Res
|
2014
|
0.88
|
|
13
|
Endoscopic-assisted closure of persistent gastrocutaneous fistula with a porcine fistula plug: report of a new technique.
|
Surg Innov
|
2010
|
0.88
|
|
14
|
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
|
Anticancer Drugs
|
2008
|
0.87
|
|
15
|
Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma.
|
J Vasc Interv Radiol
|
2013
|
0.85
|
|
16
|
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
|
Cancer Chemother Pharmacol
|
2011
|
0.85
|
|
17
|
From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.
|
J Natl Cancer Inst
|
2013
|
0.82
|
|
18
|
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
|
Invest New Drugs
|
2014
|
0.77
|
|
19
|
Promising targets and drugs in development for colorectal cancer.
|
Semin Oncol
|
2011
|
0.77
|
|
20
|
Elevated gene expression in chalcone synthase enzyme suggests an increased production of flavonoids in skin and synchronized red cell cultures of North American native grape berries.
|
DNA Cell Biol
|
2012
|
0.77
|
|
21
|
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
|
Am J Clin Oncol
|
2009
|
0.77
|
|
22
|
Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database.
|
Pancreas
|
2017
|
0.75
|